BIOMARK ANNOUNCES The U.S. Patent and Trademark Office Granted PATENT WITH CLAIMS COVERING ITS LUNG CANCER LIQUID BIOPSY ASSAY
The new family of patent granted by USPTO strengthens BioMark’s global intellectual property position in liquid biopsy and early cancer detection. Vancouver, British Columbia – (May 31st, 2023) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers […]
Press Release – BIOMARK LATEST RESULTS ACCEPTED FOR PRESENTATION AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING 2023
BIOMARK LATEST RESULTS ACCEPTED FOR PRESENTATION at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023 New analyses from a large retrospective validation study of early lung cancer metabolomics panel, underscoring strength of BioMark’s liquid biopsy platform, to be presented. Vancouver, British Columbia – (May 3rd, 2023) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) […]
BIOMARK PRESENTS NOVEL LIQUID BIOPSY DATA IN PULMONARY NEUROENDOCRINE TUMORS
BIOMARK PRESENTS NOVEL LIQUID BIOPSY DATA IN PULMONARY NEUROENDOCRINE TUMORS Vancouver, British Columbia – (March 16th, 2023) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce that novel liquid biopsy data presented this […]
BIOMARK PROVIDES THIRD QUARTER OPERATIONAL UPDATE AND 2023
BIOMARK PROVIDES THIRD QUARTER OPERATIONAL UPDATE AND 2023 Vancouver, British Columbia – (March 1st, 2022) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers reported its operational update for the third quarter ended December […]
BioMark Receives Funding, Support, Research and Development Project for Cancer Treatment Monitoring
BIOMARK RECEIVES FUNDING SUPPORTING RESEARCH AND DEVELOPMENT PROJECT FOR CANCER TREATMENT MONITORING Vancouver, British Columbia – (February 7th, 2023) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers, is pleased to announce today that […]
Biomark Announces Update From Oongoing Clinical Trial Using Its Lung Cancer Liquid Biopsy Test As It Prepares For Commercial Launch
BIOMARK ANNOUNCES UPDATE FROM ONGOING CLINICAL TRIAL USING ITS LUNG CANCER LIQUID BIOSPY TEST AS IT PREPARES FOR COMMERCIAL LAUNCH Vancouver, British Columbia – (January 11, 2023) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and […]
BIOMARK PROVIDES BUSINESS UPDATE AND SECOND QUARTER Financial RESULTS
BIOMARK PROVIDES BUSINESS UPDATE AND SECOND QUARTER Financial RESULTS Vancouver, British Columbia – (November 28, 2022) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to reports that it will amend the […]
BIOMARK’s GLIOBLASTOMA Study Published in CANCERS Demonstrates Inhibiting SAT1 sensitized cancer cells towards radiation and chemotherapy
BIOMARK’s GLIOBLASTOMA Study Published in CANCERS Demonstrates Inhibiting SAT1 Sensitized Cancer Cells Towards Radiation and Chemotherapy Vancouver, British Columbia – (October 27th, 2022) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today […]
The US Patent Office Grants BIOMARK Additional Patent for its LIQUID BIOPSY Technology
THE US PATENT OFFICE GRANTS BIOMARK ADDITIONAL PATENT FOR ITS LIQUID BIOPSY TECHNOLOGY Vancouver, British Columbia – (September 20, 2022) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that the US […]
BioMark TO PRESENT VALIDATION DATA OF ITS Multianalyte Metabolite Panel for Lung Cancer Screening at THE ESMO CONGRESS 2022
BioMark TO PRESENT VALIDATION DATA OF ITS Multianalyte Metabolite Panel for Lung Cancer Screening at THE ESMO CONGRESS 2022 Vancouver, British Columbia – (September 8, 2022) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased […]